Transforming Preclinical, Translational & Clinical Progress in Hearing Loss Treatment R&D
The 5th Inner Ear Disorders Therapeutics Summit arrives at a pivotal moment in the field, as breakthroughs in gene therapy, small molecules, and cell-based therapies reignite hope for treating hearing loss.
Following significant clinical successes from Regeneron & Eli Lilly, 2025 offers renewed optimism and momentum in genetic hearing loss treatments. However, challenges remain across preclinical, translational, and clinical stages, underscoring the need for collaboration. This event brings together leaders from biotech, pharma, VC’s and academia to address these hurdles, discuss cutting-edge research, and explore opportunities in drug-device combinations, creating a unique platform for advancing hearing loss therapeutics in 2025.
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Testimonials:
“As an attendee and contributor to the previous four Inner Ear Disorders Therapeutics Summits, I am excited to continue contributing to driving the field forward with my peers and have the opportunity for in-person discussion and networking at the 5th Annual Summit! “
Acousia Therapeutics
''Participation in this meeting will enhance the communication of science and drug development in inner ear therapy. Learn about the newest progress, needs, and challenges of inner ear drug development.''
Refreshgene Therapeutics
Confirmed Partners:
Other Events in the Sensory Series:
